BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31373112)

  • 1. Efficacy of topical Citrullus colocynthis (bitter apple) extract oil in chemotherapy-induced peripheral neuropathy: A pilot double-blind randomized placebo-controlled clinical trial.
    Rostami N; Mosavat SH; Heydarirad G; Arbab Tafti R; Heydari M
    Phytother Res; 2019 Oct; 33(10):2685-2691. PubMed ID: 31373112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Citrullus colocynthis (bitter apple) extract oil in painful diabetic neuropathy: A double-blind randomized placebo-controlled clinical trial.
    Heydari M; Homayouni K; Hashempur MH; Shams M
    J Diabetes; 2016 Mar; 8(2):246-52. PubMed ID: 25800045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of the FACT-GOG-Ntx to assess chemotherapy-induced peripheral neuropathy (CIPN) in pediatric high risk Hodgkin lymphoma: report from the Children's Oncology Group AHOD 1331 study.
    Parsons SK; Rodday AM; Pei Q; Keller FG; Wu Y; Henderson TO; Cella D; Kelly KM; Castellino SM
    J Patient Rep Outcomes; 2023 Nov; 7(1):113. PubMed ID: 37947987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study.
    Ajewole VB; Cox JE; Swan JT; Chikermane SG; Lamoth B; Iso T; Okolo LO; Ford CL; Schneider AM; Hobaugh EC; Baker KR
    Support Care Cancer; 2020 Apr; 28(4):1901-1912. PubMed ID: 31359183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical
    Heydarirad G; Cramer H; Choopani R; Gharehgozlou R; Mosavat SH; Ameri A; Pasalar M
    J Altern Complement Med; 2020 Sep; 26(9):807-812. PubMed ID: 32924550
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase III randomized, placebo-controlled study of topical amitriptyline and ketamine for chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study of 462 cancer survivors.
    Gewandter JS; Mohile SG; Heckler CE; Ryan JL; Kirshner JJ; Flynn PJ; Hopkins JO; Morrow GR
    Support Care Cancer; 2014 Jul; 22(7):1807-14. PubMed ID: 24531792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double blind, placebo controlled, phase II randomised cross-over trial investigating the use of duloxetine for the treatment of chemotherapy-induced peripheral neuropathy.
    Battaglini E; Park SB; Barnes EH; Goldstein D
    Contemp Clin Trials; 2018 Jul; 70():135-138. PubMed ID: 29680317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
    Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
    Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
    Cheng HL; Molassiotis A
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy.
    Cheng HL; Lopez V; Lam SC; Leung AKT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; De Ng TR; Suen LKP; Chan CW; Yorke J; Molassiotis A
    Health Qual Life Outcomes; 2020 Jul; 18(1):246. PubMed ID: 32703223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial to evaluate the preventive effect of lafutidine on chemotherapy-induced peripheral neuropathy in patients treated with carboplatin and paclitaxel for lung cancer.
    Cho K; Saikawa H; Hashimoto T; Katagiri H; Owada Y; Yakuwa K; Fujimura I; Utsumi Y; Akiyama M; Nagashima H; Takahashi F; Maemondo M
    Ann Palliat Med; 2023 Nov; 12(6):1136-1145. PubMed ID: 37731302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-Related Quality of Life in Cancer Survivors with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Clinical Trial.
    Bao T; Baser R; Chen C; Weitzman M; Zhang YL; Seluzicki C; Li QS; Piulson L; Zhi WI
    Oncologist; 2021 Nov; 26(11):e2070-e2078. PubMed ID: 34390283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity.
    Alberti P; Bernasconi DP; Cornblath DR; Merkies ISJ; Park SB; Velasco R; Bruna J; Psimaras D; Koeppen S; Pace A; Dorsey SG; Argyriou AA; Kalofonos HP; Briani C; Schenone A; Faber CG; Mazzeo A; Grisold W; Valsecchi M; Cavaletti G;
    Neurology; 2021 Aug; 97(7):e660-e672. PubMed ID: 34078718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial).
    Joy L; Jolien R; Marithé C; Stijn E; Laura S; Hilde L; Sandra B; Wendy N; Ruth H; Liesbeth R; Sylvana S; Sylvia H; Jeroen M
    Support Care Cancer; 2022 Jun; 30(6):5509-5517. PubMed ID: 35312857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Survivors: A Randomized Controlled Pilot Trial.
    Lu W; Giobbie-Hurder A; Freedman RA; Shin IH; Lin NU; Partridge AH; Rosenthal DS; Ligibel JA
    Oncologist; 2020 Apr; 25(4):310-318. PubMed ID: 32297442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cryocompression to Reduce Peripheral Neuropathy in Gynecologic Cancer: A Randomized Controlled Trial.
    Anastasio MK; Unnithan S; Scott A; Hayes T; Shah S; Moss HA; Erkanli A; Havrilesky LJ
    Obstet Gynecol; 2023 Dec; 142(6):1459-1467. PubMed ID: 37883997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Reported Outcome Measures in Chemotherapy-Induced Peripheral Neurotoxicity: Defining Minimal and Clinically Important Changes.
    Li T; Timmins HC; Trinh T; Mizrahi D; Harrison M; Horvath LG; Grimison P; Friedlander M; Kiernan MC; King MT; Rutherford C; Goldstein D; Park SB
    J Natl Compr Canc Netw; 2023 Feb; 21(2):125-132.e3. PubMed ID: 36791763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
    Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
    Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of oxycodone/naloxone as add-on therapy to gabapentin or pregabalin for the management of chemotherapy-induced peripheral neuropathy in Korea.
    Kim BS; Jin JY; Kwon JH; Woo IS; Ko YH; Park SY; Park HJ; Kang JH
    Asia Pac J Clin Oncol; 2018 Oct; 14(5):e448-e454. PubMed ID: 29280313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
    Hershman DL; Unger JM; Crew KD; Minasian LM; Awad D; Moinpour CM; Hansen L; Lew DL; Greenlee H; Fehrenbacher L; Wade JL; Wong SF; Hortobagyi GN; Meyskens FL; Albain KS
    J Clin Oncol; 2013 Jul; 31(20):2627-33. PubMed ID: 23733756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.